Results 171 to 180 of about 46,164 (349)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial [PDF]

, 2014
Ivan Goldberg, Rafael Gil Pina, Aitor Lanzagorta-Aresti, Rhett M. Schiffman, Charlie Liu, Marina Bejanian   +5 more
openalex   +1 more source

Facial Nerve Palsy in Malignant Otitis Externa Hospitalizations: Outcomes and Risk Factors

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To provide a description of the occurrence of facial nerve palsy in hospitalizations for malignant otitis externa and to compare the demographic characteristics, hospital traits, comorbidities, and outcomes between patients with and without palsy. Study Design Retrospective cross‐sectional database study.
Emma R. Thompson, Anthony M. Saad, Sean Z. Haimowitz, Nour H. Abdel‐Azim, Kevin Wong, Andrey Filimonov   +5 more
wiley   +1 more source

Ecofriendly Long Life Nanocomposite Sensors for Determination of Carbachol in Presence of Choline: Application in Ophthalmic Solutions and Biological Fluids. [PDF]

Sensors (Basel), 2019
Al-Harbi EA, Abdelrahman MH, El-Kosasy AM.   +2 more
europepmc   +1 more source

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital

, 2020
ResuNeha Reddy, Vadlakonda Sruthi, K SOWMINI, NagurSharone Grace   +3 more
openalex   +2 more sources

Physiologically based pharmacokinetic modeling and simulation of topiramate in populations with renal and hepatic impairment and considerations for drug–drug interactions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 510-522, March 2025.
Abstract Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics.
Shuqing Chen, Chaozhuang Shen, Yuchen Tian, Yuhe Peng, Jing Hu, Haitang Xie, Ping Yin   +6 more
wiley   +1 more source

Allergy to ophthalmic solutions [PDF]

Clin Transl Allergy, 2014
Lapeere H, Veramme J, De Zaeytijd J, Lambert J.   +3 more
europepmc   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Allergic Conjunctivitis Management: Update on Ophthalmic Solutions. [PDF]

Curr Allergy Asthma Rep
Leonardi A, Quintieri L, Presa IJ, LLoves JM, Montero J, Benítez-Del-Castillo JM, Lestón FJS, González-Mancebo E, Asero R, Groblewska A, Kuna P.   +10 more
europepmc   +1 more source

Lotilaner ophthalmic solution 0.25% in Demodex blepharitis: a profile of its use [PDF]

Yahiya Y. Syed
openalex   +1 more source

Ophthalmic Solution Dosage Form [PDF]

, 2020
National Cancer Institute
openalex   +1 more source